COMMUNIQUÉS West-GlobeNewswire

AscellaHealth Leaders Take the Stage at SIIA National Conference: Present Strategies for Managing High-Cost Claims and Building Pharma Partnerships
07/10/2025
BERWYN, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- AscellaHealth , a global partner delivering customizable solutions to support the specialty pharmaceutical industry, announces today that two of its senior leaders will [...]
Soul of Yoga Announces First-Ever Quantitative Insights and Rankings of Best Yoga Teacher Training Schools in the World
07/10/2025
The new report identifies which Yoga Alliance schools attract the most students—and which among the top 100 are rated highest by graduates. With more than 7,500 schools listed, and no previous way to sort by number of [...]
Global Innovative Platforms Announces Completion of First Phase of Breath Test Study for Early Heartworm Detection
07/10/2025
New non-invasive diagnostic may identify heartworm months earlier than current methods MAITLAND, Fla., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Global Innovative Platforms Inc. (OTC: GIPL) today announced completion of the [...]
Bavarian Nordic Reports Positive Topline Data for Mpox/Smallpox Vaccine in Pediatric Population
07/10/2025
Primary endpoint was met in clinical study, demonstrating a comparable safety profile and a non-inferior immune response for MVA-BN in children aged 2-11 years compared to adults. Results will support filing for label [...]
BioAdaptives® Announces Commercial Launch of MyndMed™ Following Successful Pilot Testing
07/10/2025
Comprehensive cognitive-support formula now available online; company scaling production for anticipated Q4 demand LAS VEGAS, Oct. 07, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT) today announced [...]
NeXtGen Biologics Announces Issuance Of A Third New Patent Covering Axolotl-Derived Technology
07/10/2025
GAINESVILLE, Fla., Oct. 07, 2025 (GLOBE NEWSWIRE) -- NeXtGen Biologics announces the issuance of a third U.S. patent, US12311079, on May 27, 2025, as part of its suite of U.S. and foreign patents directed to [...]
Checkerspot and Huvepharma Partner to Commercialize Groundbreaking Human Milk Fat Analog
07/10/2025
Clearing a Major Technological Hurdle, Checkerspot & Huvepharma Ready to Scale Production of the Novel, Direct Analog for Human Milk Fat Alameda, Calif (USA) and Sofia (Bulgaria), Oct. 07, 2025 (GLOBE NEWSWIRE) -- [...]
Ipsen - Septembre 2025 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
07/10/2025
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
Ipsen - September 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
07/10/2025
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
OXB expands US footprint with acquisition of commercial-scale viral vector facility in North Carolina
07/10/2025
OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’s previously announced strategy to add US GMP capacity across drug substance and [...]
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
07/10/2025
SAN MATEO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences
07/10/2025
BEDFORD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation [...]
Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025
07/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked [...]
Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity
07/10/2025
RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateaued Preclinical results show that a single point-in-time treatment with RJVA-002 has the potential to achieve [...]
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
07/10/2025
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will [...]
Jade Biosciences Announces $135 Million Private Placement
07/10/2025
SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in- [...]
Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases
07/10/2025
JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy with the goal of delivering deeper, more durable B cell depletion with less [...]
Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01
07/10/2025
Dr. Kates’ experience as chair of the landmark Phase 3 BRIDGE bladder cancer trial and dedication to patient care will be invaluable to the NDV-01 Phase 3 program Phase 3 program for NDV-01 expected to begin in H1 2026 [...]
Esaote enters the field of neurosurgery by presenting an innovative intraoperative MRI system
07/10/2025
I-Genius is the result of Esaote’s research and collaboration with neurosurgeons. The results achieved using MRI systems in brain glioma surgery were presented at EANS annual Congress held in Vienna The medical and [...]

Pages